Applied DNA Positions LinearDNAT Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): By:Investor contact: Sanjay M. Hurry, Applied DNA Sci
  • Source:
    Business Wire, August 17, 2020, 4pp
  • Additional Information
    • Abstract:
      Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR) based DNA manufacturing that enables in vitro diagnostics, pre clinical nucleic acid based therapeutic drug candidates, supply chain security, anti counterfeiting and anti theft technology, today announced that it has filed a nonprovisional patent application with the United States Patent and Trademark Office (USPTO) entitled "Methods and Systems of PCR Based Recombinant Adeno Associated Virus (AAV) Manufacture" (the "Patent")...